Nanocrystal technology for drug formulation and delivery

被引:55
作者
Chang, Tzu-Lan [1 ]
Zhan, Honglei [1 ]
Liang, Danni [2 ]
Liang, Jun F. [1 ]
机构
[1] Charles V Schaefer Sch Engn & Sci, Stevens Inst Technol, Dept Chem Chem Biol & Biomed Engn, Hoboken, NJ 07030 USA
[2] SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA
关键词
drug nanocrystal; nanotechnology; formulation; bioavailability; stabilizers; drug delivery; NANOSUSPENSIONS; PARTICLES;
D O I
10.1007/s11705-015-1509-3
中图分类号
TQ [化学工业];
学科分类号
0817 ;
摘要
With the development of modern technology like high throughput screening, combinatorial chemistry and computer aid drug design, the drug discovery process has been dramatically accelerated. However, new drug candidates often exhibit poor aqueous or even organic medium solubility. Additionally, many of them may have low dissolution velocity and low oral bioavailability. Nanocrystal formulation sheds new light on advanced drug development. Due to small (nano- or micro- meters) sizes, the increased surface-volume ratio leads to dramatically enhanced drug dissolution velocity and saturation solubility. The simplicity in preparation and the potential for various administration routes allow drug nanocrystals to be a novel drug delivery system for specific diseases (i.e. cancer). In addition to the comprehensive review of different technologies and methods in drug nanocrystal preparation, suspension, and stabilization, we will also compare nano- and micro- sized drug crystals in pharmaceutical applications and discuss current nanocrystal drugs on the market and their limitations.
引用
收藏
页码:1 / 14
页数:14
相关论文
共 85 条
[41]  
Liu R, 2000, WATER INSOLUBLE DRUG, P455
[42]   Paclitaxel Nanocrystals for Overcoming Multidrug Resistance in Cancer [J].
Liu, Yang ;
Huang, Leaf ;
Liu, Feng .
MOLECULAR PHARMACEUTICS, 2010, 7 (03) :863-869
[43]  
Liversidge G.G., 1992, U.S. Patent, Patent No. [5145684, US5145684]
[44]   DRUG PARTICLE-SIZE REDUCTION FOR DECREASING GASTRIC IRRITANCY AND ENHANCING ABSORPTION OF NAPROXEN IN RATS [J].
LIVERSIDGE, GG ;
CONZENTINO, P .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1995, 125 (02) :309-313
[45]   Development and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation [J].
Lu, Ying ;
Wang, Zhao-hui ;
Li, Tonglei ;
McNally, Helen ;
Park, Kinam ;
Sturek, Michael .
JOURNAL OF CONTROLLED RELEASE, 2014, 176 :76-85
[46]  
Mansell P, 2007, NANOCRYSTALS COULD B
[47]   Nanosizing: a formulation approach for poorly-water-soluble compounds [J].
Merisko-Liversidge, E ;
Liversidge, GG ;
Cooper, ER .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 18 (02) :113-120
[48]   Nanosizing for oral and parenteral drug delivery: A perspective on formulating poorly-water soluble compounds using wet media milling technology [J].
Merisko-Liversidge, Elaine ;
Liversidge, Gary G. .
ADVANCED DRUG DELIVERY REVIEWS, 2011, 63 (06) :427-440
[49]   Drug Nanoparticles: Formulating Poorly Water-Soluble Compounds [J].
Merisko-Liversidge, Elaine M. ;
Liversidge, Gary G. .
TOXICOLOGIC PATHOLOGY, 2008, 36 (01) :43-48
[50]   New method for the effective production of ultrafine drug nanocrystals [J].
Moeschwitzer, Jan ;
Mueller, Rainer H. .
JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY, 2006, 6 (9-10) :3145-3153